This perspective underscores the inadequacy of simplistic "symptom-pill" approaches and highlights the need for personalized, multidimensional care, including alternative pharmaceutical formulations of PDE5i, such as the orodispersible film, that may enhance discretion, acceptability, and adherence.
Sansone et al. (Thu,) studied this question.